A Phase 2b Open-Label Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies
Brief description of study
This is a Phase 2b, single-arm, open-label, multicenter study of selinexor (80 mg) with low-dose (20 mg) dexamethasone given orally to patients with heavily pretreated MM quad-refractory to bortezomib, carfilzomib, lenalidomide, and pomalidomide
Clinical Study Identifier: s15-00126
ClinicalTrials.gov Identifier: NCTs15-00126
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
